Déjanos tus datos para afiliarte

* Llamada sin costo

Producción científica internacional

Producción científica internacional a cargo de nuestros médicos

Año 2016

 

Molecular and Clinical Oncology

  1. Aguilar A, Pinto JA, Araujo J, Fajardo W, Bravo L, Pinillos L, Vallejos C. Control of cervical cancer in Peru: current barriers and challenges for the future. Molecular and Clinical Oncology.

Ver enlace

 

Science Translational Oncology

  1. Balko JM, Schwarz LJ, Luo N, Estrada MV, Giltnane JM, Dávila-González D, Wang K, Sánchez V, Dean PT, Combs SE, Hicks D, Pinto JA, Landis MD, Doimi FD, Yelensky R, Miller VA, Stephens PJ, Rimm DL, Gómez H, Chang J4, Sanders ME, Cook RS, Arteaga C. Triple-negative breast cancers with amplification of JAK2 at the 9p24 locus demonstrate JAK2-specific dependence. Sci Transl Med 2016;8:334ra53.

Ver enlace

 

Oncotarget

 

  1. Araujo JM, Prado A, Cardenas NK, Zaharia M, Dyer R, Doimi F, Bravo L, Pinillos L, Morante Z, Aguilar A, Mas L, Gomez HL, Vallejos CS, Rolfo C, Pinto JA. Repeated observation of immune gene sets enrichment in women with non-small cell lung cancer. Oncotarget (In press). 2016.

Ver enlace

 

npj Genomic Medicine

 

  1. Pinto JA, Araujo J, Cardenas NK, Morante Z, Doimi F, Vidaurre T, Balko JM, Gomez A prognostic signature based on three-genes expression in triple-negative breast tumours with residual disease. npj Genomic Medicine 2016;1.

Ver enlace

 

International Journal of cancer

  1. Rachel Skinner S, Wheeler CM, Romanowski B, Castellsagué X, Lazcano-Ponce E, Rowena Del Rosario-Raymundo M, Vallejos C, Minkina G, Pereira Da Silva D, McNeil S, Prilepskaya V, Gogotadze I, Money D, Garland SM, Romanenko V, Harper DM, Levin MJ, Chatterjee A, Geeraerts B, Struyf F, Dubin G, Bozonnat MC, Rosillon D, Baril L; VIVIANE study group. Progression of HPV infection to detectable cervical lesions or clearance in adult women: Analysis of the control arm of the VIVIANE study. Int J Cancer 2016 May 15;138:2428-38.ddsfdsf

Ver enlace

 

 

Año 2015

 

The New England Journal of Medicine

 

  1. Moore HC, Unger JM, Phillips KA, Boyle F, Hitre E, Porter D, Francis PA, Goldstein LJ, Gomez HL, Vallejos CS, Partridge AH, Dakhil SR, Garcia AA, Gralow J, Lombard JM, Forbes JF, Martino S, Barlow WE, Fabian CJ, Minasian L, Meyskens FL Jr, Gelber RD, Hortobagyi GN, Albain KS; POEMS/S0230 Investigators. Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. N Engl J Med. 2015 Mar 5;372(10):923-32.

http://www.nejm.org/doi/full/10.1056/NEJMoa1413204#t=article

Clinical research and trials

  1. Gómez HL, Pinto J A, Castañeda C, Vallejos CS. Current barriers for developing clinical research in Latin America: A cross-sectional survey of medical oncologists. Clin Res 2015;1:22-28.

http://oatext.com/pdf/CRT-1-108.pdf

World Lung Cancer Conference

  1. Vallejos C, Flores CJ, Aguilar A, Vigil C, Sarria G, Pinillos L. Survival of cancer patients treated at Oncosalud-AUNA. Eur J Cancer 2015;(51):S145-S146.

 

Clinical reumathology

 

  1. Rodríguez Jaillier JC, Posada Arango AM, Martínez Pérez DA. Challenges faced in Latin America for the implementation of an ideal health-care model for rheumatoid arthritis patients: are we ready? Clin Rheumatol. 2015;34 Suppl 1:S79-93

https://www.researchgate.net/publication/280777946_Challenges_faced_in_Latin_America_for_the_implementation_of_an_ideal_health-care_model_for_rheumatoid_arthritis_patients_are_we_ready

 

SPIE Proceedings

 

  1. Fonseca P, Mendoza J, Wainer J, Ferrer J, Pinto J, Guerrero J, Castaneda B. Automatic breast density classification using a convolutional neural network architecture search procedure. Proc. SPIE 9414, Medical Imaging 2015: Computer-Aided Diagnosis, 941428.

http://proceedings.spiedigitallibrary.org/proceeding.aspx?articleid=2211266

 

  1. Casado FL, Manrique S, Guerrero J, Pinto J, Ferrer J, Castañeda B. Characterization of breast density in women from Lima, Peru. Proc. SPIE 9416, Medical Imaging 2015: Image Perception, Observer Performance, and Technology Assessment, 94161B.

 

  1. Angulo A, Ferrer J, Pinto J, Lavarello R, Guerrero J, Castaneda B. Experimental assessment of an automatic breast density classification algorithm based on principal component analysis applied to histogram data. SPIE 9287, 10th International Symposium on Medical Information Processing and Analysis, 92870E.

http://proceedings.spiedigitallibrary.org/proceeding.aspx?articleid=2108485

 

ASCO MEETING 2015

  1. Joseph A. Pinto, Jhajaira Araujo, Nadezhda K Cardenas, Justin M. Balko, Carlos L. Arteaga and Henry Gomez. triple negative and basal breast tumors with residual disease. J Clin Oncol (Meeting Abstracts) May 2015 vol. 33 no. 15_suppl 1097

http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/1097?sid=6cb4dbdc-2d5c-4d33-80ab-097ed68f3ed0

  1. Cindy Alcarraz, Mivael Olivera, Johana Muñiz, Zaida Morante, Rossana Ruiz, Natalia Valdiviezo and Luis Alberto Mas Lopez. Carboplatin and paclitaxel dose dense as neoadjuvant chemotherapy follow by interval cytoreduction in advanced ovarian cancer. J Clin Oncol (Meeting Abstracts) May 2015 Vol 33, No 15_suppl (May 20 Supplement), 2015: e16553

http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/e16553?sid=ba3ac8eb-11c5-46b0-a55a-91e748fb59f2

  1. Zaida Morante, Henry Gomez, Joseph A. Pinto, Claudio J Flores, Carlos Manuel Morante Deza, Luis Cano, Luis Taxa, Silvia P. Neciosup, Jhajaira Araujo and Luís Más. Clinical and prognostic features of Chromophobe renal cell carcinoma. J Clin Oncol (Meeting Abstracts) May 2015 vol. 33 no. 15_suppl e15631

http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/e15631?sid=89be12a7-59eb-4100-a3da-521c4780b9c0

  1. Carlos O Munive, Maria F Muro, Greenlandia Ferreyros, Miluska Mayuri, Joseph A. Pinto, Jhajaira Araujo and Henry Gomez. Outcome of breast cáncer with symptomatic bone marrow involvement. J Clin Oncol (Meeting Abstracts) May 2015 vol. 33 no. 15_suppl e12611

http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/e12611?sid=ed3dc883-94a1-4449-b2da-d95bc9fdbbb7

  1. Jose Luis Buleje Sono, Francia Del Pilar Huaman, Maria Guevara-Fujita, Joseph A. Pinto, Jhajaira Araujo, Carlos Vigil, Jaime Ponce, Frank Lizaraso, Alfredo Aguilar, Ricardo Fujita and Henry Gomez. Screening for genomic rearrangements in BRCA1 and BRCA2 genes in 16 Peruvian breast cancer families by Multiplex Ligation-dependent Probe Amplification (MLPA). Journal of Clinical Oncology, 2015 ASCO Annual Meeting (May 29 – June 2, 2015). Vol 33, No 15_suppl (May 20 Supplement), 2015: e12553

http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/e12553?sid=f31a9304-9d82-4930-8984-8ade56b33241

 

SABCS 2015

 

  1. Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, Geyer Jr CE, Dees EC, Perez EA, Olson Jr JA, Zujweski J, Keane MM, Gomez Moreno HL, Reddi RP, Goggins TF, Mayer IA, Brufsky AM, Toppmeyer DL, Kaklamani VG, Atkins JN, Berenberg JL, Sledge Jr GW. Prospective trial of endocrine therapy alone in patients with estrogen receptor positive, HER2-negative, node-negative breast cancer: Results of the TAILORx low risk registry. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P2-08-01

http://cancerres.aacrjournals.org/content/76/4_Supplement/P2-08-01.short

 

  1. Morante Z, Araujo J, Fuentes H, Neciosup S, Gomez H. Phyllodes tumor of the breast, clinicopathological features and prognostics factors in a retrospective cohort with 7-year follow-up. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P6-10-18.

http://cancerres.aacrjournals.org/content/76/4_Supplement/P6-10-18.short

 

Año 2014

 

World Cancer Report 

 

  1. Vallejos C. Cancer Control in Peru: “El Plan Esperanza”- The Hope Plan. In: World Cancer Report 2014. International Agency for Cancer Research 2014. p. 584-85.

 

http://www.iarc.fr/en/publications/books/wcr/wcr-order.php

 

Cancer Discovery 

 

  1. Balko JM, Giltnane J, Wang K, Schwarz LJ, Young CD, Cook RS, Owens P, Sanders ME, Kuba MG, Sánchez V, Kurupi R, Moore PD, Pinto JA, Doimi FD, Gomez H, Horiuchi D, Goga A, Lehmann BD, Bauer JA, Pietenpol JA, Ross J, Palmer GA, Yelensky R, Cronin MT, Miller VA, Stephens PJ, Arteaga CL. El perfil molecular del cáncer de mama triple negativo residual luego de quimioterapia neoadyuvante identifica dianas terapéuticas acccionables. Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets. Cancer Discovery. 2014, 4:232-245.

 

(texto libre)

http://cancerdiscovery.aacrjournals.org/content/4/2/232.long

Journal of Thoracic Oncology (Supplement of LALCA Conference)

  1. Pinto J, Prado A, Cárdenas N, Valdiviezo P,  Neciosup S, Aguilar A, Sarria G, Zaharia M, Flores C, Mas L. El incremento de la susceptibilidad al cáncer de pulmón relacionada al consumo de tabaco en mujeres no se explica mediante la expresión de los genes de reparación del DNA. Increased susceptibility to lung cancer related to smoking in women is not explained by the expression of DNA repair genes. J Thorac Oncol 2014; 9(S3):P2.40.

 

(texto libre)

http://pdfs.journals.lww.com/jto/2014/09003/IASLC_6th_Latin_American_Conference_on_Lung.1.pdf?token=method|ExpireAbsolute;source|Journals;ttl|1417648977295;payload|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;hash|QbHymsuF4MyaELAgeGpXvQ==

 

 

  1. Mas L, Pinillos L, Vallejos C, Flores C, Pinto J, Suazo JF, Valdiviezo P, Aguilar A. Sobrevida global en pacientes con cáncer de pulmón tratados en Oncosalud – AUNA. Overall survival in lung cancer patients treated at Oncosalud – AUNA. J Thorac Oncol 2014;9(S3):P1.07.

 

http://pdfs.journals.lww.com/jto/2014/09003/IASLC_6th_Latin_American_Conference_on_Lung.1.pdf?token=method|ExpireAbsolute;source|Journals;ttl|1417648977295;payload|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;hash|QbHymsuF4MyaELAgeGpXvQ==

 

  1. Aguilar A, Mas L, Pinillos L, Flores C, Pinto J, Valdiviezo P, Suazo JF, Vallejos C. Efectos de la terapia dirigida en la sobrevida global en pacientes con cáncer de pulmón. Effect of targeted therapy in the overall survival in patients with lung cancer. J Thorac Oncol 2014;9(S3):P2.07

 

http://pdfs.journals.lww.com/jto/2014/09003/IASLC_6th_Latin_American_Conference_on_Lung.1.pdf?token=method|ExpireAbsolute;source|Journals;ttl|1417648977295;payload|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;hash|QbHymsuF4MyaELAgeGpXvQ==

 

Jornadas Paulistas de Radiología 2014

  1. Moscol D. Taxa L. Aguilar J, Guerrero J. Oncocitoma renal gigante: un reporte de caso en Perú. Giant renal oncocytoma: a case report in Peru. JPR 2014. 02.008.

Journal of Clinical Oncology (Supplement of  ASCO Meeting 2014)

  1. Rojas K, Flores R, Flores C, Pinto J, Gómez H, Castañeda Densidad mamográfica y sobrevida libre de recurrencia en cáncer de mama localmente avanzado [HR+, HER2-] tratado con quimioterapia neoadyuvante. Mamographic density and disease-free survival in [HR+, HER2-] locally advanced breast cancer treated with neoadjuvant chemotherapy. J Clin Oncol 32, 2014 (suppl; abstr e11536)

http://meetinglibrary.asco.org/content/125999-144

 

  1. Moore H, Unger J, Phillips K, Moore H, Unger J, Phillips K, Boyle F, Hitre E, Porter D, Francis P, Minasian L, Gelber R, Goldstein L, Gomez H, Vallejos C, Partridge A, Dakhil S, Martino S, Barlow W, Fabian C, Meyskens F, Hortobagyi G, Albain K. Estudio de fase III (Estudio de prevención de la menopausa temprana [POEMS]-SWOG S0230) de un análogo de LHRH durante la quimioterapia (CT) para reducir la falla ovárica en estadios tempranos de cáncer de mama con receptores hormonales negativos: Estudio internacional de intergrupos de SWOG, IBCSG, ECOG, and CALGB (Alianza).  Phase III trial (Prevention of Early Menopause Study [POEMS]-SWOG S0230) of LHRH analog during chemotherapy (CT) to reduce ovarian failure in early-stage, hormone receptor-negative breast cancer: An international Intergroup trial of SWOG, IBCSG, ECOG, and CALGB (Alliance). J Clin Oncol 32:5s, 2014 (suppl; abstr LBA505)

http://meetinglibrary.asco.org/content/129172-144

 

  1. Aguilar A, Valdiviezo P, Ibañez C, Bravo M, Gonzales P, Kato S, Garrido M, Brañes J, Pizarro, Barriga J, Hector Leon M, Bustamante E, Alonso C, Bravo E, Arab C, Barra A, Barrena N, Jimenez P, Cuello M, Owen G. Quimioterapia personalizada para pacientes con cáncer de ovario. Personalized cancer therapy for ovarian cancer patients. J Clin Oncol 32, 2014 (suppl; abstr e16521)

http://meetinglibrary.asco.org/content/132339-144

 

  1. Wang U, Fetterly G, Pitzonka L, Wang E, Fetterly G, Pitzonka L, Brady W, Tan W, Greene J, Munster D, Vigil C, Mendler J, Becker M, Carr-O’Dwyer K, Wetzler M, Liesveld J. Estudio de fase I del pepticuerpo neutralizador de la angiopoyetina 1/2, trebananib, en leucemia mieloide aguda. Phase 1 study of the angiopoietin 1/2 neutralizing peptibody, trebananib, in acute myeloid leukemia. J Clin Oncol 32:5s, 2014 (suppl; abstr 7082)

http://meetinglibrary.asco.org/content/132806-144

 

  1. Pinto J, Flores C, Valdiviezo P, Aguilar A, Suazo J, Zaharia M, Dyer R, Vigil C, Vallejos C, Gomez H. Firma de 5 genes basados en la señalización de TLR4 como predictor para el riesgo de recurrencia a distancia en cáncer de mama tratado con quimioterapia neoadyuvante con antraciclinas y taxanos. A 5-gene signature based on TLR4 signaling as predictive of risk of distant relapse in breast cancer treated with taxane-anthracycline neoadjuvant chemotherapy. J Clin Oncol 32:5s, 2014 (suppl; abstr 11066)

http://meetinglibrary.asco.org/content/132622-144

 

  1. Valdiviezo P, Flores C, Mas L, Aguilar A, Neciosup S, Pinto J, Zaharia M, Gomez H, Vallejos C. Expresión de receptores tipo toll en siete neoplasias.  Expression of toll-like receptors in seven malignant tumors. J Clin Oncol 32, 2014 (suppl; abstr e22088)

http://meetinglibrary.asco.org/content/135205-144

 

United States & Canadian Academy of Pathology Meeting 2014

 

  1. Giltnane J, Balko J Kuba G, Schwarz L, Sanders M, Sanchez V, Pinto J, Doimi F,  Gomez H, Ross J, Palmer G, Yelensky R, Cronin M, Miller V, Stephens P, Cook R, Arteaga C. La amplificación del gen MCL1 está asociada con la sobreexpresión de MCL-1 en cáncer de mama triple negativo. MCL1 Gene Amplification is Associated with MCL-1 Overexpression in Triple Negative Breast Cancer. USCAP 2014 Annual Meeting (Abstract #452434).

 

 

SABCS 2014

 

  1. Loi S, Denkert C, Salgado R, O’Hely M, Savas P, Beavis, PA, Darcy, PK, Combs S, Rimm DL, Giltnane JM, Estrada MV, Sanders ME, Cook RS, Wang K, Miller VA, Stephens PJ, Yelensky R, Pinto JA, Doimi F, Gomez H, Arteaga CL, Balko JM. Reduced tumor lymphocytic infiltration in the residual disease (RD) of post-neoadjuvant chemotherapy (NAC) triple-negative breast cancers (TNBC) is associated with Ras/MAPK activation and poorer survival. SABCS 2014 (PARA SER PRESENTADO EN DICIEMBRE).
  2. Schwarz LJ, Balko JM, Giltnane JM, Sanders ME, Wang K, Lin NU, Miller VA, Stephens PJ, Yelensky R, Pinto JA, Gomez H, Landis M, Chang J, Arteaga CL. Enrichment of janus kinase-2 (JAK2)-amplified tumor cell populations in triple-negative breast cancers (TNBC) during chemotherapy treatment. SABCS 2014 (PARA SER PRESENTADO EN DICIEMBRE).
  3. Giltane J, Balko J, Stricker T, Young C, Estrada V, Wagle N,  Van Allen E, Mu X, Sanchez V, Farley J, Fitzgerald K, Graber A, Pinto J, Doimi F, Gómez H, Rizzo M, Julian T, Abramson V, Mayer I, Kelley M, Yenamandra A, Wheeler F, Sanders M, Garraway L, Meszoely I, Arteaga Cl. Reduced tumor lymphocytic infiltration in the residual disease (RD) of post-neoadjuvant chemotherapy (NAC) triple-negative breast cancers (TNBC) is associated with Ras/MAPK activation and poorer survival. SABCS 2014 (PARA SER PRESENTADO EN DICIEMBRE).

 

Año 2013

Clinical Cancer Research

 

  1. Dennison JB, Molina JR, Mitra S, González-Angulo AM, Balko JM, Kuba MG, Sanders ME, Pinto JA, Gómez HL, Arteaga CL, Brown RE, Mills GB. Lactato deshidrogenasa B: un marcador metabólico de respuesta a la quimioterapia neoadyuvante en cáncer de mama.  Lactate dehydrogenase B: a metabolic marker of response to neoadjuvant chemotherapy in breast cancer. Clin Cancer Res. 2013 Jul 1;19(13):3703-13.

http://clincancerres.aacrjournals.org/content/19/13/3703.full.pdf+html

 

Cancer Research (Supplement of SABCS 2013)

  1. Contreras AC, Acosta V, Torres LG, Ferri N, López H, Marin E, Juan P, Gil ME, Pinto JA, Flores CF, Gómez HL. El tumor no palpable es un factor sustituto para la sobrevida libre de enfermedad en el cáncer de mama temprano. Non-palpable tumor is a surrogate factor for longer disease free survival in early breast cancer: Evaluation of a 23 years-Venezuelan cohort. Cancer Res 2013;73(24 Suppl): Abstract nr P6-06-41.

http://cancerres.aacrjournals.org/content/73/24_Supplement/P6-06-41

 

  1. Balko JM, Giltnane JM, Schwarz LJ, Sanders ME, Wang K, Harris LN, Lin NU, Miller VA, Stephens PJ, Yelensky R, Pinto JA, Gomez H, Arteaga CL. Las amplificaciones de JAK2 están enriquecidas en el cáncer de mama triple negativo (TNBC) luego de quimioterapia neoadyuvante y predicen un pobre pronóstico. JAK2 amplifications are enriched in triple negative breast cancers (TNBCs) after neoadjuvant chemotherapy and predict poor prognosis. Cancer Res 2013;73(24 Suppl): Abstract nr S6-01.

http://cancerres.aacrjournals.org/content/73/24_Supplement/S6-01

 

35th Annual international IEEE EMBS conference 2013

 

  1. Ferrer J, Castaneda B, Pinto J, Guerrero J. Nueva clasificación de la densidad mamaria basada en el Filtro de  Nagao y segmentación de densidad a priori. A novel automatic breast density classification based in Nagao Filter and a priori dense segmentation. Conf Proc IEEE Eng Med Biol Soc. 2013;2013:4450-3.

 

Gynecologic Oncology

 

  1. Levinson KL, Abuelo C, Salmeron J, Chyung E, Zou J, Belinson SE, Wang G, Ortiz CS, Vallejos CS, Belinson JL. EL Estudio de Prevención del Cáncer Cervical (PERCAPS): La tecnología que hace accesible al despistaje. The Peru Cervical Cancer Prevention Study (PERCAPS): the technology to make screening accessible. Gynecol Oncol. 2013 May;129(2):318-23.

http://www.gynecologiconcology-online.net/article/S0090-8258(13)00063-2/abstract

 

International Journal of Gynecological Cancer

 

  1. Levinson KL, Abuelo C, Chyung E, Salmeron J, Belinson SE, Sologuren CV, Ortiz CS, Vallejos MJ, Belinson JL. EL Estudio de Prevención del Cáncer Cervical (PERCAPS): investigación basada en la participación de la comunidad en Manchay, Perú. The Peru cervical cancer prevention study (PERCAPS): community-based participatory research in Manchay, Peru. Int J Gynecol Cancer. 2013 Jan;23(1):141-7.

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3529758/

 

European Journal of Cancer (Supplement of Markers in Cancer Meeting 2013)

 

  1. Pinto J, Valdiviezo P, Aguilar A, Flores C, Velazco R, Suazo J, Vallejos C, Gómez H, División de Investigación, Oncosalud- Auna. Lima, Peru. Genes involucrados en la transducción de la señal de TLR4 como factores pronósticos para la sobrevida luego de quimioterapia neoadyuvante con antraciclinas y taxanos en cáncer de mama invasivo. Genes involved in TLR4 signal transduction as prognostic factors for survival following Taxane-Anthracycline neoadjuvant chemotherapy for invasive breast cancer. European Journal of Cancer Vol. 49 Supplement 4, Pages S35-S36.

http://www.eortc.be/temp/EJC%20abstract%20book.pdf

 

European Cancer Organization  Meeting – ECCO 2013

 

  1. Flores C, Casanova L. Factores pronósticos para la sobrevida global en Linfoma No Hodgkin: Hazard ratio no lineal de algunas covariables continuas. Prognostic factors for overall survival in Non-Hodgkin Lymphoma: Nonlinear hazard ratio of some continuous covariates Abstract number: 3638

http://meetinglibrary.asco.org/content/118083-132

 

ASCO Educational Book 2013

 

  1. Vallejos C. Plan Nacional para la prevención, detección temprana y control del cáncer en Perú. National plan for prevention, early detection, and cancer control in Peru. Am Soc Clin Oncol Educ Book. 2013:245-8.

http://meetinglibrary.asco.org/content/222-132

 

Journal of Clinical Oncology (Supplement of ASCO Meeting 2013)

 

  1. Suazo J, Valdiviezo P, Flores C, Iberico J, Pinto J, Aguilar A, Vigil C, Gomez H, Vallejos C. Incidencia del Cáncer de Mama en una cohorte grande de mujeres afiliadas a un sistema prepago. Breast cancer incidence in a large cohort of Peruvian women affiliated to a pre-paid system. J Clin Oncol 31, 2013 (suppl; abstr e12570).

http://meetinglibrary.asco.org/content/117924-132

 

  1. Suazo J, Valdiviezo P, Flores C, Iberico J, Pinto J, Aguilar A, Vigil C, Gomez H, Vallejos C. Incidencia del Cáncer de Próstata en una cohorte grande de hombres afiliados a un sistema prepago. Prostate cancer incidence in a large cohort of Peruvian men affiliated to a prepaid system. J Clin Oncol 31, 2013 (suppl; abstr e12566).

http://meetinglibrary.asco.org/content/117991-132

 

  1. Pinto J, Flores C, Valdiviezo P, Velazco R, Garay M, Suazo J, Aguilar A, Gomez H, Vallejos C. Un sistema de puntuación basado en la expresión de los receptores tipo toll para predecir el pronóstico en los subtipos moleculares de cáncer de mama tratados con quimioterapia neoadyuvante (NAC). A score based in toll-like receptors expression to predict prognostic in molecular subtypes of breast cancer treated with neoadjuvant chemotherapy (NAC). J Clin Oncol 31, 2013 (suppl; abstr e22165).

http://meetinglibrary.asco.org/content/117780-132

 

  1. Castañeda C, Flores R, Rojas K, Flores C, Morante Z, Pacheco C, Ruiz R, Calderón G, Gómez H, Vidaurre T. Hallazgos mamográficos en carcinoma de mama localmente avanzado tratado con quimioterapia neoadyuvante. Mammographic findings in locally advanced breast carcinoma treated with neoadjuvant chemotherapy. J Clin Oncol 31, 2013 (suppl; abstr e12538)

http://meetinglibrary.asco.org/content/115800-132

 

  1. Flores C, Casanova L. Factores pronósticos para la supervivencia global en linfomas no Hodgkin:Efectos no lineares de covariables continuas. Prognostic factors for overall survival in non-Hodgkin lymphomas: Nonlinear effect of continuous covariates. J Clin Oncol 31, 2013 (suppl; abstr e19538)

http://meetinglibrary.asco.org/content/118083-132

 

 

Año 2012

 

Lancet Oncology 2012

 

  1. Pettengell R, Coiffier B, Narayanan G, de Mendoza FH, Digumarti R, Gomez H, Zinzani PL, Schiller G, Rizzieri D, Boland G, Cernohous P, Wang L, Kuepfer C, Gorbatchevsky I, Singer JW. Pixantrone dimaleato versus otros agentes quimioterapeuticos como tratamiento de salvataje de un solo agente en pacientes con Linfoma no-Hodgkin agresivo recurrente o refractario: estudio de fase 3, multicéntrico, abierto, randomizado. Pixantrone dimaleate versus other chemotherapeutic agents as a single-agent salvage treatment in patients with relapsed or refractory aggressive non-Hodgkin lymphoma: a phase 3, multicentre, open-label, randomised trial. Lancet Oncol. 2012 Jul; 13(7):e285.

http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(12)70212-7/fulltext

 

Nature Medicine 2012

 

  1. Balko JM, Cook RS, Vaught DB, Kuba MG, Miller TW, Bhola NE, Sanders ME, Granja-Ingram NM, Smith JJ, Meszoely IM, Salter J, Dowsett M, Stemke-Hale K, González-Angulo AM, Mills GB, Pinto JA, Gómez HL, Arteaga CL. El perfil molecular del cáncer de mama residual luego de la quimioterapia neoadyuvante identifica la deficiencia de DUSP4 como un mecanismo de resistencia a fármacos. Profiling of residual breast cancers after neoadjuvant chemotherapy identifies DUSP4 deficiency as a mechanism of drug resistance. Nat Med. 2012 Jul;18(7):1052-9.

(texto libre)

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3693569/

 

 

 

Hematology Oncology and Stem Cell Therapy 2012

 

  1. Gómez HL, Samanéz C, Campana F, Neciosup SP, Vera L, Casanova L, Leon J, Flores C, de Mendoza FH, Casteñeda CA, Pinto JA, Vallejos CS. Adición de amifostine al régimen CHOP en pacientes mayores con linfoma no Hodgkin agresivo: estudio de fase II que mostró una reducción de la toxicidad sin alterar la sobrevida a largo plazo. Addition of amifostine to the CHOP regimen in elderly patients with aggressive non-Hodgkin lymphoma: a phase II trial showing reduction in toxicity without altering long-term survival. Hematol Oncol Stem Cell Ther. 2012; 5(3):152-7.

(texto libre)

http://www.ncbi.nlm.nih.gov/pubmed/23095791

 

Annals of Oncology (Supplement of European Society for medical Oncology –  ESMO Meeting 2012)

 

  1. Vallejos C. Investigación independiente sobre el cáncer en Latino América: Un nuevo modelo. Independent Cancer Research In Latin America: A New Model. Annals of Oncology 23 (Supplement 9): ix65, 2012

 

 

Journal of Clinical Oncology (Supplement of ASCO Meeting 2012)

 

  1. Munive C, Gallo A, Neciosup S, Doimi F, Dyer R, Pinto J, Lopez-Ilasaca M, Gomez H. Frecuencia de las mutaciones de PIK3CA en cáncer de mama HER2+ resecado quirúrgicamente en una cohorte hispana. Frequency of PIK3CA mutations in HER2+ surgically resected breast cancers in a Hispanic cohort. J Clin Oncol 30, 2012 (suppl; abstr e11066)

http://meetinglibrary.asco.org/content/101476-114

 

  1. Alfaro M, Baldeos R, Rosales B, Berenguel M, Aguilar A. Evaluación de la escala conductual del dolor en pacientes agónicos con cáncer: Experiencia en total care – un servicio de cuidado en el hogar al final de la vida. Pain assessment behavioral scale in agonic cancer patients: Experience in total care—An end-of-life care home service. J Clin Oncol 30, 2012 (suppl; abstr e19636)

http://meetinglibrary.asco.org/content/101051-114

 

  1. Neciosup S, Quesada J, Callacondo D, Aguilar I. Prevalencia de la asociación de microlitiasis testicular con tumores testiculares y extragonadales de células germinales en una población Latino americana. Prevalence of testicular microlithiasis association with testicular and extragonadal germ cell tumors in a Latin American population. J Clin Oncol 30, 2012 (suppl 5; abstr 331)

http://meetinglibrary.asco.org/content/89772-116

 

  1. Balko J, Sanders M, Kuba M, Pinto J, Doimi F, Gomez H, Arteaga C. Firma genética de la vía de activación de MEK para predecir la supervivencia en cáncer de mama triple negativo. A gene expression signature of MEK pathway activation to predict survival in triple-negative breast cancer. J Clin Oncol 30, 2012 (suppl; abstr 1024)

http://meetinglibrary.asco.org/content/98384-114

 

  1. Schwarz L, Vallejos C, Neciosup S, Pinto J, Vidaurre T, Ferreyros G, Gómez H. Meningismo como un pobre factor de riesgo en pacientes con cancer de mama con recurrencia en el sistema nervioso central (CNS). Meningism as a poor risk factor in breast cancer patients with relapse in central nervous system (CNS). J Clin Oncol 30, 2012 (suppl; abstr e11518)

http://meetinglibrary.asco.org/content/101386-114

 

  1. Castaneda C, Gómez H, Pinto J, Schwarz L, Vigil C, Vallejos C. Factores de pobre pronóstico para la sobrevida en pacientes con cáncer de mama luego de recurrencia en el sistema nervioso central. Poor prognostic factors of post-CNS recurrence survival in breast cancer patients. J Clin Oncol 30, 2012 (suppl; abstr 2097)

http://meetinglibrary.asco.org/content/101289-114

 

  1. Neciosup S, Callacondo D, Rua O, Rojas J, Quesada J, Schwarz L, Aguilar I, Más L, Gómez H, Vallejos C. Factores de supervivencia y pronóstico luego de la respuesta completa a la primera línea de quimioterapia con cisplatino en pacientes con seminoma testicular avanzado: Experiencia en el Instituto Nacional de Enfermedades Neoplásicas. Survival and prognostic factors after complete response to first-line cisplatin-based chemotherapy in patients with advanced testicular seminoma: The Instituto Nacional de Enfermedades Neoplásicas experience. J Clin Oncol 30, 2012 (suppl; abstr e15036)

http://meetinglibrary.asco.org/content/101553-114

 

Journal of Clinical Oncology (Supplement of Markers in Cancer 2012)

 

  1. Pinto J, Doimi F, Balko J, Arteaga C, Gómez H. Expresión de KI-67 en tumores de mama triple negativo residuales luego de quimioterapia neoadyuvante para predecir la sobrevida libre de recurrencia. Ki-67 expression in residual triple-negative breast tumors after neoadjuvant chemotherapy to predict for recurrence-free survival. J Clin Oncol 30: 2012 (suppl 30; abstr 89)

http://meetinglibrary.asco.org/content/103686-127

 

Cancer Research (Supplement of SABCS 2012)

 

  1. Balko JM, Wang K, Sanders ME, Kuba MG, Pinto JA, Doimi F, Gomez H, Palmer G, Cronin MT, Miller VA, Yelensky R, Stephens PJ, Areaga CL. El perfil molecular del cáncer de mama triple negativo luego de la quimioterapia neoadyuvante identifica alteraciones moleculares como dianas para el tratamiento de la enfermedad refractaria residual. Profiling of triple-negative breast cancers after neoadjuvant chemotherapy identifies targetable molecular alterations in the treatment-refractory residual disease. Cancer Research: December 15, 2012; Volume 72, Issue 24, Supplement 3

(texto libre)

http://www.ncbi.nlm.nih.gov/pubmed/24356096

 

  1. Gomez HL, Pinto JA, Schwarz JL, Vigil CE, and Vallejos CS. Variables medidas luego de la recurrencia en el Sistema Nervioso Central (SNC), excepto por el inmunofenotipo, identifican grupos de pacientes con cáncer de mama con una sobrevida más corta luego de la recurrencia en el SNC. Variables measured at Central Nervous System (CNS) relapse, but not Immunophenotype, identify groups of breast cancer patients with shorter post CNS-relapse survival. Cancer Res December 15, 2012; 72(24 Supplement): P6-07-20.

http://cancerres.aacrjournals.org/content/72/24_Supplement/P6-07-20.abstract?sid=27cb84c3-7e5a-4379-b395-1f17abef0756

 

 

  1. Gomez HL, Schwarz LJ, Vasquez J, Neciosup SP, Pinto JA, Vidaurre T, Ferreyros G, and Vallejos CS. Signos y síntomas de la recurrencia en el sistema nervioso central (SNC) en pacientes con cáncer de mama con carcinomatosis leptomeningeal relacionada con una menor sobrevida luego de la recurrencia. Signs and symptoms at central nervous system (CNS) relapse in breast cancer patients with Leptomeningeal carcinomatosis related with shorter survival after recurrence. Cancer Res December 15, 2012; 72(24 Supplement): P6-07-21

http://cancerres.aacrjournals.org/content/72/24_Supplement/P6-07-21.abstract?sid=23be7adc-460a-40c1-aae7-7ce482e34b88